321352-54-9

Basic information

• Product Name: Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with (2R)-5-bromo-2,3-dihydro-1H-inden-2-amine (1:1) OTHER CA INDEX NAMES: 1H-Inden-2-amine, 5-bromo-2,3-dihydro-, (2R)-, (1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonate
• CAS NO: 321352-54-9
• Molecular Formula: C10H16O4S.C9H10BrN
• Molecular Weight: 444.39
• Mol File: 321352-54-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with (2R)-5-bromo-2,3-dihydro-1H-inden-2-amine (1:1) OTHER CA INDEX NAMES: 1H-Inden-2-amine, 5-bromo-2,3-dihydro-, (2R)-, (1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with (2R)-5-bromo-2,3-dihydro-1H-inden-2-amine (1:1) OTHER CA INDEX NAMES: 1H-Inden-2-amine, 5-bromo-2,3-dihydro-, (2R)-, (1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonate(321352-54-9)
• EPA Substance Registry System: Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with (2R)-5-bromo-2,3-dihydro-1H-inden-2-amine (1:1) OTHER CA INDEX NAMES: 1H-Inden-2-amine, 5-bromo-2,3-dihydro-, (2R)-, (1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonate(321352-54-9)

Safety Data

• Hazardous Substances Data: 321352-54-9(Hazardous Substances Data)

Upstream product

• 2338-18-3 2-aminoindane hydrochloride 
• 321352-52-7 5-bromo-2-aminoindane hydrobromide 
• 3144-16-9 (1S)-10-camphorsulfonic acid 
• 936025-36-4 4-methylmorpholinium D-10-camphorsulfonate 
• 73536-88-6 5-bromo-2-aminoindane 

Downstream Products

• 1199827-76-3 (R)-benzyl 5-bromo-2,3-dihydro-1H-inden-2-ylcarbamate 
• 1199827-80-9 (R)-benzyl 5-(hydroxymethyl)-2,3-dihydro-1H-inden-2-ylcarbamate 
• 1199827-78-5 (R)-methyl 2-(benzyloxycarbonylamino)-2,3-dihydro-1H-indene-5-carboxylate 
• 1199827-82-1 (R)-benzyl-5-((4-(hydroxymethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)-2,3-dihydro-1H-inden-2-ylcarbamate 
• 1199828-62-0 (R)-N-(5-((4-(hydroxymethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)-2,3-dihydro-1H-inden-2-yl)-2-chlorobenzenesulfonamide 

Relevant articles and documents

Structure based evolution of a novel series of positive modulators of the AMPA receptor

Starting from compound 1, we utilized biostructural data to successfully evolve an existing series into a new chemotype with a promising overall profile, exemplified by 19.

INDANE DERIVATIVES AS AMPA RECEPTOR MODULATORS

The present invention relates to a heterocyclic derivative according to formula (I); wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceut

COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE

Compounds of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, are disclosed: wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; each R4, which may be the same or different, is C1-6alkyl, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, nitro, amino, monoC1-4alkylamino or diC1-4alkylamino; p is 0, 1 or 2; n is 1 or 2; R5 and R6, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano, amino, monoC1-4alkylamino or diC1-4alkylamino; and Het is thienyl, pyridyl, pyrimidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, pyrrolyl, quinolyl, thiazolyl or furyl, each of which may be substituted by one or more groups independently selected from the list consisting of C1-6alkyl, C1-6alkoxy, acetyl, halogen, haloC1-6alkyl, cyano, nitro, amino, monoC1-4alkylamino and diC1-4alkylamino. Methods of preparation of the compounds, and uses thereof in medicine, for example treatment of schizophrenia, are also disclosed.